胃癌组织原钙黏蛋白10 mRNA表达水平与预后的相关性

背景与目的：编码原钙黏蛋白10(protocadherin-10，PCDH10)的PCDH10基因启动子甲基化与胃癌患者不良预后相关。但PCDH10表达水平与胃癌预后的关系不明确。该研究旨在分析PCDH10表达水平与胃癌预后及临床病理因素间的关系，寻找预测胃癌患者复发及死亡风险的指标。方法：采用实时荧光定量聚合酶链反应(real-time lfuorescent quantitative polymerase chain reaction，RTFQ-PCR)方法检测115对胃癌组织与相应癌旁组织PCDH10 mRNA的表达水平，分析PCDH10 mRNA的表达水平与预后及临床病理因素的关系。采用Logis-tic回归分析建立预测患者5年内复发或死亡风险的模型。结果：PCDH10 mRNA低表达组与非低表达组相比，无进展生存时间(progression-free survival，PFS)与总生存时间(overall survival，OS)显著延长(P值分别为0.046与0.033)，淋巴结转移较少(P=0.001)，TNM分期较早(P=0.001)。Cox单因素分析发现，Lauren分型、T分期、N分期、M分期及PCDH10 mRNA表达水平与PFS及OS显著相关。包含PCDH10作为参数的Logistic回归模型对胃癌患者术后5年内复发或死亡风险的预测效率与仅包含传统临床病理学参数的Logistic回归模型的预测效率相当。结论：PCDH10低表达胃癌患者淋巴结转移较少，TNM分期较早，预后较好，可以作为预测胃癌患者预后的辅助指标。基于PCDH10表达水平的Logistic回归模型可以在淋巴结转移情况不明时起到辅助判断患者预后的作用。

Correlation between mRNA expression of protocadherin-10 and prognosis in gastric cancer

Background and purpose:Promoter methylation ofPCDH10, a gene encoding protocadherin 10, has been found to be correlated to poor prognosis in gastric cancer (GC) patients. However, the relationship between the expression of PCDH10 and prognosis in GC remained unknown. This study aimed to explore the relationship be-tween the expression of PCDH10 and clinicopathological features and prognosis of GC, and to identify biomarker for predictions of recurrence and survival of GC.Methods:mRNA expressions of PCDH10 in 115 pairs of GC tissues and adjacent normal tissues were detected by real-time lfuorescence quantitative polymerase chain reaction (RTFQ-PCR). The correlation between PCDH10 expression level and clinicopathological features and prognosis of GC was analyzed. Prediction models for 5-year recurrence and 5-year survival were established using logistic regression method.Results:Progression-free survival (PFS) and overall survival (OS) were signiifcantly prolonged in patients with PCDH10 low expression compared to patients without PCDH10 low expression (P=0.046 andP=0.033 respectively). PCDH10 low expression signiifcantly correlated with less lymph node metastasis (P=0.001) and earlier TNM staging (P=0.001), and was more common in female than in male (P=0.040). The mRNA expression of PCDH10 did not correlate with age, Lauren classiifcation, T stage, neural invasion or vascular invasion. Univariate Cox analysis showed Lauren classiifca-tion, T stage, N stage, M stage and PCDH10 expression signiifcantly correlated with PFS and OS. Logistic regression models for the prediction of 5-year recurrence or 5-year survival based on clinicopathological features included Lauren classiifcation, T stage, N stage and M stage as variables. Logistic regression models for the prediction of 5-year recur-rence or 5-year survival based on PCDH10 expression included Lauren classiifcation, T stage, M stage and PCDH10 expression level but not N stage as variables. The models based on PCDH10 expression had the same effciencies as models based on clinical parameters in predicting 5-year recurrence or 5-year survival for GC patients.Conclusion:PCDH10 low expression correlated with better prognosis, less lymph node metastasis and earlier TNM stage in GC patients. Low expression of PCDH10 may be a biomarker of better survival for GC patients. Logistic regression model based on PCDH10 mRNA expression may serve as a prediction model when patients have unknown lymph node metas-tasis status.